Basel Medical prices $7.98M registered direct offering at $1.33 per unit

Basel Medical Group Ltd (NASDAQ: BMGL), a Singapore-based medical services provider, has priced a registered direct offering of 6,000,000 units at $1.33 per unit, with total gross proceeds of $7.98 million before deducting commissions and expenses, according to a company statement.

The company estimates net proceeds from the offering will be approximately $7.28 million. Each unit consists of one ordinary share or one pre-funded warrant, along with one common warrant to purchase one additional ordinary share.

Common warrants are exercisable immediately at an exercise price equal to 110% of the public offering price per unit and will expire five years from the date of issuance. Holders may exercise common warrants on a zero-cash basis, meaning the company does not expect to receive additional funds upon their exercise. If all 6,000,000 common warrants are exercised on a zero-cash basis, an aggregate of 6,000,000 ordinary shares would be issued without additional payment to the company.

Prior to the offering, Basel Medical had 1,582,111 ordinary shares outstanding. Upon completion, the company will have 7,582,111 ordinary shares and 6,000,000 common warrants outstanding.

The company, along with its executive officers, directors, and shareholders owning 5% or more of ordinary shares, have entered into 180-day lock-up agreements restricting the sale or disposition of shares without prior written approval from the placement agent, Cathay Securities, Inc.

The offering is registered under a Form F-1 registration statement declared effective by the U.S. Securities and Exchange Commission on September 29, 2026. Sichenzia Ross Ference Carmel LLP is serving as U.S. securities counsel to the company, and Hunter Taubman Fischer & Li LLC is acting as U.S. securities counsel for the placement agent.

You May Also Be Interested In

• Basel Medical raises $7.98M in registered direct offering
• Microchip Technology acquires radiation-hardened chip maker VORAGO
• Outlook Therapeutics names Greg DiPasquale as CCO ahead of U.S. launch